Pharma: Clinic Roundup
Eli Lilly and Co., of Indianapolis, stopped its Phase II study (BACC) for LY2886721, a beta secretase inhibitor being investigated as a once-daily treatment for its potential to slow the progression of Alzheimer's disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter